Biosimilar Labeling In US Needs Greater Transparency, BIO And PhRMA Say
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration's current approach to biosimilar labeling lacks transparency and requires changes to align with the agency's own Transparency Initiative, a joint citizen petition from two biopharmaceutical trade groups suggests1.
You may also be interested in...
Biosimilar Labeling: US FDA’s Final Guidance Means Status Quo For Sponsors
Advice document, little changed from a March 2016 draft, continues to reflect agency’s view that clinical studies supporting a demonstration of biosimilarity should not be included in labeling.
Biosimilar Labeling: US FDA’s Final Guidance Means Status Quo For Sponsors
Advice document, little changed from a March 2016 draft, continues to reflect agency’s view that clinical studies supporting a demonstration of biosimilarity should not be included in labeling.
Biosimilar Labeling: Should FDA Just Throw Up Its Hands And Finalize Guidance?
Brand and generic industries are on opposite sides of spectrum on most issues; there is mutual opposition, however, to the use of a meaningless four-letter suffix in the proper name of a product.